NEW YORK, October 20, 2017 /PRNewswire/ --
According to data providedby Grand View Research Inc., the global cancer immunotherapy market is expected to reach USD 118.8 billion by 2025. The market is expected to benefit from introduction of newer drug classes, such as target receptors for
"Furthermore, increase in number of approvals for new immunotherapeutic drugs is driving the global market. Introduction of new molecules has been proving to be beneficial for patients who are not responding to chemotherapy. Several new immunotherapeutic options, such as immunomodulators and CAR-T cell therapy, are in the pipeline and are being tested for their ability to provide better cancer treatment," Grand View Research indicates.
Regen Biopharma, Inc. (OTCQB: RGBP) on October 16th announced breaking news that it, "believes it has taken full advantage of its recent prior discovery in developing small molecule drugs that activate NR2F6. The Company recently reported that it identified key structural elements in small molecules that make them active and specific towards the NR2F6 target. Now, further chemical testing has revealed dozens of compounds which activate NR2F6 which contain the key motif discovered.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity."
"Because our medicinal chemists were able to identify key structural elements in prior experiments, we can now add those elements to new compounds and screen other compounds that have that structure," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "We did this and discovered dozens of new compounds that profoundly activated NR2F6. We are now selecting the best for further study."
"We are very excited at how well the medicinal chemistry program is working," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "We will file additional composition of matter patents around these structures shortly and we should be able to focus on just one or two of the best ones moving forward."
Advaxis, Inc. (NASDAQ: ADXS) is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. On September 19, 2017, the company announced two abstracts were selected for presentation at the 32nd annual Society for Immunotherapy of Cancer (SITC) meeting. The conference is renowned for its scientific exchange, education and mission to improve patient outcomes through advancement of science and the cancer immunotherapy field. "We're grateful to be sharing these meaningful findings with the rest of the immunotherapy community," said Dr. Robert Petit, chief scientific officer at Advaxis. "Each poster presentation allows members of our field to discuss new findings and approaches, with the goal of bringing improved treatment options to patients. OncoSec Medical Incorporated (NASDAQ: ONCS) is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. Recently, the company announced updated Phase 2 clinical and immune monitoring data from patients treated with its investigational therapy, ImmunoPulse® IL-12 as a monotherapy versus the combination of ImmunoPulse IL-12 and the approved anti-PD-1 therapy pembrolizumab. These data were presented in an oral presentation at the 2017 9th World Congress of Melanoma - A Joint Meeting with the Society for Melanoma Research, and continue to support the rationale for the Company's recently initiated global, open-label, Phase 2b registration directed trial, PISCES/KEYNOTE-695. Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is developing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. Recently, the company announced that an abstract describing new data for IPI-549 has been selected as a late-breaking presentation during an oral session at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place in National Harbor, MD, November 10 - 12. Additionally, a clinical trials in progress poster will also be presented on the Phase 1/1b clinical study which is ongoing to explore the safety and activity of IPI-549 both as a monotherapy and in combination with Opdivo® (nivolumab), a PD-1 immune checkpoint inhibitor, in patients with advanced solid tumors. IPI-549 is believed to be the only PI3K-gamma inhibitor in clinical development. Curis, Inc. (NASDAQ: CRIS) is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis.
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information: Media Contact: firstname.lastname@example.org +1-877-601-1879
Subscribe to our Free Newsletters!
Gastrointestinal bleeding refers to hemorrhage that occurs from one or more portions of the ...
Simple, quick, and easy methods can be included in your diet or exercise routine, which can help ...
Necrotizing fasciitis is a rare life threatening bacterial infection of the tissue below the skin ...View All